Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma

被引:31
作者
Feng, Hong [1 ,2 ]
Yang, Fujun [3 ]
Qiao, Lihong [4 ]
Zhou, Kai [1 ,2 ]
Wang, Junfei [5 ]
Zhang, Jiao [6 ]
Tian, Tian [5 ]
Du, Ying [6 ]
Shangguan, Hong [5 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Ctr Canc, Jinan, Peoples R China
[2] Shandong First Med Univ, Ctr Canc, Shandong Prov Hosp, Jinan, Peoples R China
[3] Weihai Municipal Hosp, Dept Oncol, Weihai, Peoples R China
[4] Peoples Hosp Pingyi Cty, Dept Internal Med, Pingyi, Peoples R China
[5] Shandong Univ, Dept Resp & Crit Care Med, Qilu Hosp, Jinan, Peoples R China
[6] Genecast Biotechnol Co Ltd, Dept Translat Med, Wuxi, Jiangsu, Peoples R China
关键词
lung adenocarcinoma; tertiary lymphoid structures; gene signature; tumor mutational burden; driver gene mutations; PD-L1; EXPRESSION; B-CELLS; CANCER; SURVIVAL; IMMUNOTHERAPY; LANDSCAPE; IMMUNITY;
D O I
10.3389/fonc.2021.693234
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Lung adenocarcinoma (LUAD) is a highly mortal cancer. Tertiary lymphoid structures (TLS) are ectopic lymphoid organs with similar morphological and molecular characters to secondary lymphoid organ. The aim of this study is to investigate the prognostic effect of a gene signature associated with TLSs, including B-cell-specific genes. Methods Clinical data of 515 LUAD patients in the TGCA cohort were used to examine the relationship of TLS signature with immune microenvironment, tumor mutational burden (TMB), and driver gene mutations. Patients were divided into the TLS signature high group and TLS signature low group, and comparative analysis of survival and its influencing factors between the two groups was performed. The resulting data were then validated in the GSE37745 cohort. Results TLS signature high group had significantly better overall survival (OS) and progression-free interval (PFI) as well as significantly higher infiltration of immune cell subsets, cancer immune cycle (CIC) signature except for immunogram score2 (IGS2), and expression of major checkpoint genes than the TLS signature low group. Notably, while TLS signature was not markedly associated with TMB and mutation frequencies of driver genes, there were significant differences in overall survival of patients with given mutation status of EGFR, KRAS, BRAF and TP53 genes between the TLS signature high and low groups. Conclusion This study provided evidence that LUAD patients with high TLS signature had a favorable immune microenvironment and better prognosis, suggesting that TLS signature is an independent positive prognostic factor for LUAD patients.
引用
收藏
页数:12
相关论文
共 47 条
[1]   Prognostic value of PDL1 expression in stage III Non-Small Cell Lung Cancer (NSCLC) treated by chemo-radiotherapy (CRT) [J].
Adam, J. ;
Boros, A. ;
Lacas, B. ;
Lacroix, L. ;
Pignon, J. P. ;
Caramella, C. ;
Planchard, D. ;
Levy, A. ;
Besse, B. ;
Le Pechoux, C. .
EUROPEAN JOURNAL OF CANCER, 2015, 51 :S604-S604
[2]   Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma [J].
Baba, Yoshifumi ;
Nomoto, Daichi ;
Okadome, Kazuo ;
Ishimoto, Takatsugu ;
Iwatsuki, Masaaki ;
Miyamoto, Yuji ;
Yoshida, Naoya ;
Baba, Hideo .
CANCER SCIENCE, 2020, 111 (09) :3132-3141
[3]   Global Epidemiology of Lung Cancer [J].
Barta, Julie A. ;
Powell, Charles A. ;
Wisnivesky, Juan P. .
ANNALS OF GLOBAL HEALTH, 2019, 85 (01)
[4]   Understanding the tumor immune microenvironment (TIME) for effective therapy [J].
Binnewies, Mikhail ;
Roberts, Edward W. ;
Kersten, Kelly ;
Chan, Vincent ;
Fearon, Douglas F. ;
Merad, Miriam ;
Coussens, Lisa M. ;
Gabrilovich, Dmitry I. ;
Ostrand-Rosenberg, Suzanne ;
Hedrick, Catherine C. ;
Vonderheide, Robert H. ;
Pittet, Mikael J. ;
Jain, Rakesh K. ;
Zou, Weiping ;
Howcroft, T. Kevin ;
Woodhouse, Elisa C. ;
Weinberg, Robert A. ;
Krummel, Matthew F. .
NATURE MEDICINE, 2018, 24 (05) :541-550
[5]   PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review [J].
Brody, Robert ;
Zhang, Yiduo ;
Ballas, Marc ;
Siddiqui, Mohd Kashif ;
Gupta, Palvi ;
Barker, Craig ;
Midha, Anita ;
Walker, Jill .
LUNG CANCER, 2017, 112 :200-215
[6]   Tertiary lymphoid structures improve immunotherapy and survival in melanoma [J].
Cabrita, Rita ;
Lauss, Martin ;
Sanna, Adriana ;
Donia, Marco ;
Larsen, Mathilde Skaarup ;
Mitra, Shamik ;
Johansson, Iva ;
Phung, Bengt ;
Harbst, Katja ;
Vallon-Christersson, Johan ;
van Schoiack, Alison ;
Loevgren, Kristina ;
Warren, Sarah ;
Jirstroem, Karin ;
Olsson, Hakan ;
Pietras, Kristian ;
Ingvar, Christian ;
Isaksson, Karolin ;
Schadendorf, Dirk ;
Schmidt, Henrik ;
Bastholt, Lars ;
Carneiro, Ana ;
Wargo, Jennifer A. ;
Svane, Inge Marie ;
Jonsson, Goran .
NATURE, 2020, 577 (7791) :561-+
[7]   Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade [J].
Charoentong, Pornpimol ;
Finotello, Francesca ;
Angelova, Mihaela ;
Mayer, Clemens ;
Efremova, Mirjana ;
Rieder, Dietmar ;
Hackl, Hubert ;
Trajanoski, Zlatko .
CELL REPORTS, 2017, 18 (01) :248-262
[8]  
Chen YB, 2012, TUMORI, V98, P751, DOI 10.1700/1217.13499
[9]   Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) [J].
Cottrell, T. R. ;
Thompson, E. D. ;
Forde, P. M. ;
Stein, J. E. ;
Duffield, A. S. ;
Anagnostou, V. ;
Rekhtman, N. ;
Anders, R. A. ;
Cuda, J. D. ;
Illei, P. B. ;
Gabrielson, E. ;
Askin, F. B. ;
Niknafs, N. ;
Smith, K. N. ;
Velez, M. J. ;
Sauters, J. L. ;
Isbell, J. M. ;
Jones, D. R. ;
Battafarano, R. J. ;
Yang, S. C. ;
Danilova, L. ;
Wolchok, J. D. ;
Topalian, S. L. ;
Velculescu, V. E. ;
Pardoll, D. M. ;
Brahmer, J. R. ;
Hellmann, M. D. ;
Chaft, J. E. ;
Cimino-Mathews, A. ;
Taube, J. M. .
ANNALS OF ONCOLOGY, 2018, 29 (08) :1853-1860
[10]   Embryonic FAP+ lymphoid tissue organizer cells generate the reticular network of adult lymph nodes [J].
Denton, Alice E. ;
Carr, Edward J. ;
Magiera, Lukasz P. ;
Watts, Andrew J. B. ;
Fearon, Douglas T. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2019, 216 (10) :2242-2252